Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Big cap medtech disappoints – but still beats pharma.
GE arrives to the spin-out party fashionably late.